Rx-360 Launches The “Traceability Data Exchange Architecture Work Group”
Rx-360 is pleased to announce the establishment of a new collaborative work group being set up to support serialisation and track and trace legislation that is evolving globally.
This work group will focus on developing conceptual models for the interoperable exchange of information needed to comply with global regulations. The work group will develop several models that will be discussed at a high level and measured for its merits and impact on the supply chain. The effort will be fast paced and result in a whitepaper for discussion at industry forums by year end and the options could be considered for global pilots.
“This workgroup is a good example of how Rx-360 operates. We are gathering the best minds in the industry to tackle a complex unmet need in the interest of enhancing patient safety. We don’t achieve interoperable systems without addressing the complexities of data exchange” said Rx-360 Chairman Brian Johnson. This workgroup will be tri-chaired by Lloyd Mager (Abbvie), Peggy Staver (Pfizer), and Brian Rezach (Actavis). A call for participation from all industry segments will be issued shortly.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.